Impatto Sociale | Trial Clinici
Impatto Sociale Trial Clinici
Rifaximin delayed release (400 mg tablet) for the prevention of recurrent acute diverticulitis and diverticular complications. (...) - (Prof.ssa Carolina CIACCI, Prof.ssa Iovino)
2017 Study Code: REDIV/002/17 Protocol Title: "Rifaximin delayed release (400 mg tablet) for the prevention of recurrent acute diverticulitis and diverticular complications. A phase II, multicenter, double-blind, placebo-controlled, randomized clinical trial (The ROAD trial)" Study promoter: Alfasigma S.p.A Codice Eudract: 2017-002708-28 2018 Study Code: MLN0002-401 - in corso
| Codice EudraCT | 2017-002708-28 2018 | |
| Inizio sperimentazione | 1 Gennaio 2021 |
Relief of heartburn and epigastric pain comparing Neobianacid® with omeprazole: a randomized, double blind, double dummy, reference product controlled, parallel group (...) ( C.CIACCI, P.Iovino)
2019 Protocol Title: Relief of heartburn and epigastric pain comparing Neobianacid® with omeprazole: a randomized, double blind, double dummy, reference product controlled, parallel group, non-inferiority clinical study EudraCT number: 2015-005216-15 Study promoter: Aboca S.p.A. Società Agricola,Località Aboca, 20 52037 Sansepolcro Arezzo (Italy) - in corso
| Codice EudraCT | 2015-005216-15 | |
| Inizio sperimentazione | 1 Gennaio 2021 |
